Literature DB >> 9465360

The prevalence and detection of substance use disorders among inpatients ages 18 to 49: an opportunity for prevention.

R L Brown1, T Leonard, L A Saunders, O Papasouliotis.   

Abstract

BACKGROUND: Previous studies have found that substance use disorders are prevalent among inpatients of general medical hospitals. These studies were limited in the validity of their measures, their failure to distinguish between current and lifetime disorders, or their lack of attention to drugs other than alcohol.
METHODS: The current study used validate diagnostic instruments to measure current and lifetime alcohol and other drugs abuse and dependence among patients ages 18 through 49. Additionally, this study assessed the sensitivity and specificity of four substance abuse screening questions. Patients were recruited from the general medical, general surgery, and orthopedics services of a university hospital in Madison, Wisconsin. The sample included 363 patients, or 86.4% of those recruited.
RESULTS: The current and lifetime prevalence rates of substance use disorders were 21.8 and 49.6%, respectively. The prevalence rates of current problems were 16.3%, alcohol only; 2.5%, other drugs only; and 3.0%, alcohol and other drugs. Males had nearly a 30% current prevalence of current substance use disorders. The CAGE Questions Adapted to Include Drugs exhibited 70.9% sensitivity and 75.7% specificity.
CONCLUSIONS: At one hospital, and perhaps at others, an alcohol and drug screening, assessment, and intervention program may have the potential to prevent future health and social problems.

Entities:  

Mesh:

Year:  1998        PMID: 9465360     DOI: 10.1006/pmed.1997.0250

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  22 in total

1.  Screening patients for alcohol, tobacco, and other drug misuse: the role of brief interventions.

Authors:  C A Aristeiguieta
Journal:  West J Med       Date:  2000-01

2.  Opioid-related US hospital discharges by type, 1993-2016.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2019-05-10

3.  Psychological distress after major burn injury.

Authors:  James A Fauerbach; Jodi McKibben; O Joseph Bienvenu; Gina Magyar-Russell; Michael T Smith; Radha Holavanahalli; David R Patterson; Shelley A Wiechman; Patricia Blakeney; Dennis Lezotte
Journal:  Psychosom Med       Date:  2007-06       Impact factor: 4.312

4.  Adverse impact of coercive treatments on psychiatric inpatients' satisfaction with care.

Authors:  Jennifer L Strauss; Jennifer B Zervakis; Karen M Stechuchak; Maren K Olsen; Jeffrey Swanson; Marvin S Swartz; Morris Weinberger; Christine E Marx; Patrick S Calhoun; Daniel W Bradford; Marian I Butterfield; Eugene Z Oddone
Journal:  Community Ment Health J       Date:  2012-09-28

5.  Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.

Authors:  Arne Kristian Skulberg; Ida Tylleskar; Turid Nilsen; Sissel Skarra; Øyvind Salvesen; Trond Sand; Thorsteinn Loftsson; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-03-22       Impact factor: 2.953

6.  Pilot feasibility trial of dual contingency management for cigarette smoking cessation and weight maintenance among weight-concerned female smokers.

Authors:  Erika Litvin Bloom; Laura Hunt; Jennifer Tidey; Susan E Ramsey
Journal:  Exp Clin Psychopharmacol       Date:  2019-10-24       Impact factor: 3.157

7.  Inpatient Addiction Consultation for Hospitalized Patients Increases Post-Discharge Abstinence and Reduces Addiction Severity.

Authors:  Sarah E Wakeman; Joshua P Metlay; Yuchiao Chang; Grace E Herman; Nancy A Rigotti
Journal:  J Gen Intern Med       Date:  2017-05-19       Impact factor: 5.128

8.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

9.  Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Sissel Skarra; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-08-24       Impact factor: 2.953

10.  Lumbar magnetic resonance imaging hypolordosis in symptomatic patients: association with paraspinal muscle spasms.

Authors:  John W Gilbert; Greg R Wheeler; Benjamin B Storey; Gregory E Mick; Stephanie L Herder; Gay Richardson; William H Wyttenbach; J Chad Martin
Journal:  J Chiropr Med       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.